

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q96716

Yoshinobu YAMAZAKI, et al.

Appln. No.: 10/598,533

Group Art Unit: 1614

Confirmation No.: 6983

Examiner: NOT YET ASSIGNED

Filed: September 1, 2006

For: MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF
OVERACTIVE BLADDER ACCOMPANYING NERVOUS DISORDER

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT
U.S. Appl. No.: 10/598,533

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

Gekkan Hodanren and Geriatr Med are written in Japanese without any translation, Applicants believe that the enclosed English translation of the International Preliminary Report on patentability (Chapter I) with written opinion of the International Searching Authority received December 22, 2006, provides a concise explanation of the relevance of these Japanese language references.

If the Examiner believe more information is necessary, the Examiner is requested to contact the undersigned.

Otherwise we will assume that all is in order with these two references. With respect to Journal of Pharmacy Pharmacology, the page numbers 975-98 in the International Search Report seems to be a mistake, because the references ends with page 982.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/598,533

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Respectfully submitted,



/Peter D. Olexy/

Peter D. Olexy

Registration No. 24,513

Date: March 12, 2007